

b.) IN THE ABSTRACT

Please amend the abstract at page 60 to read as follows.

Abstract of the Disclosure

The present invention relates to a compound E2F-inhibiting compounds are represented by the general formula (I): R<sup>1</sup>-A-R<sup>2</sup> [I] (wherein R<sup>1</sup> represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxy carbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a hydrogen atom; R<sup>2</sup> represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of the E2F family); or a pharmaceutically acceptable salt thereof, which are useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which abnormal cellular growth is responsible.